Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults ...

Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for ...

The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Dragon’s blood, a traditional Chinese medicine resin, shows promise in treating ulcerative colitis (UC). Research identified ...

For decades, scientists have puzzled over why smoking makes Crohn’s disease worse but seems to protect people from ulcerative ...

Johnson & Johnson received approval for a subcutaneous induction regimen of Tremfya to treat ulcerative colitis from the Food and Drug Administration. The pharmaceutical giant said Friday it now ...